We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMWL icon
1576
American Well
AMWL
$185M
$391K ﹤0.01%
+771
New +$446K
IGV icon
1577
iShares Expanded Tech-Software Sector ETF
IGV
$12.2B
$390K ﹤0.01%
+5,500
New +$364K
MOS icon
1578
The Mosaic Company
MOS
$7.1B
$390K ﹤0.01%
+16,965
New +$342K
WW
1579
DELISTED
WW International
WW
$390K ﹤0.01%
+15,998
New +$416K
RITM icon
1580
Rithm Capital
RITM
$5.15B
$388K ﹤0.01%
+39,020
New +$345K
VRT icon
1581
Vertiv
VRT
$110B
$387K ﹤0.01%
20,705
-103,409
-83% -$1.9M
MACK
1582
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$385K ﹤0.01%
+55,848
New +$275K
DLTR icon
1583
Dollar Tree
DLTR
$24.1B
$384K ﹤0.01%
3,553
-467,049
-99% -$46.9M
PCVX icon
1584
Vaxcyte
PCVX
$8.01B
$383K ﹤0.01%
14,426
-9,027
-38% -$336K
JFU
1585
9F Inc
JFU
$23.5M
$381K ﹤0.01%
+18,309
New +$474K
ATRS
1586
DELISTED
Antares Pharma, Inc.
ATRS
$381K ﹤0.01%
95,522
-138,205
-59% -$447K
OXM icon
1587
Oxford Industries
OXM
$602M
$377K ﹤0.01%
+5,752
New +$297K
BIP icon
1588
Brookfield Infrastructure Partners
BIP
$18.6B
$376K ﹤0.01%
11,400
+2,805
+33% +$91.3K
FVRR icon
1589
Fiverr
FVRR
$398M
$374K ﹤0.01%
1,915
-9,572
-83% -$1.73M
UNG icon
1590
United States Natural Gas Fund
UNG
$458M
$374K ﹤0.01%
+10,157
New +$438K
YELP icon
1591
Yelp
YELP
$1.45B
$374K ﹤0.01%
11,438
-15,921
-58% -$418K
IEZ icon
1592
iShares US Oil Equipment & Services ETF
IEZ
$363M
$372K ﹤0.01%
33,058
+10,992
+50% +$102K
ZDGE icon
1593
Zedge
ZDGE
$38.7M
$370K ﹤0.01%
+61,263
New +$211K
DUO
1594
Fangdd Network Group
DUO
$23.4M
$364K ﹤0.01%
+13
New +$343K
SAGE
1595
DELISTED
Sage Therapeutics
SAGE
$360K ﹤0.01%
4,156
-7,671
-65% -$565K
TRIL
1596
DELISTED
Trillium Therapeutics Inc.
TRIL
$360K ﹤0.01%
+24,482
New +$353K
FSKR
1597
DELISTED
FS KKR Capital Corp. II
FSKR
$360K ﹤0.01%
+21,951
New +$351K
SBRA icon
1598
Sabra Healthcare REIT
SBRA
$5.65B
$359K ﹤0.01%
+20,644
New +$329K
KC
1599
Kingsoft Cloud Holdings
KC
$2.97B
$358K ﹤0.01%
+8,209
New +$304K
REGI
1600
DELISTED
Renewable Energy Group, Inc.
REGI
$358K ﹤0.01%
5,050
-4,645
-48% -$284K

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.